Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) EBITDA Margin (2020 - 2022)

Historic EBITDA Margin for Immuneering (IMRX) over the last 3 years, with Q4 2022 value amounting to 2886419.34%.

  • Immuneering's EBITDA Margin fell 28807077700.0% to 2886419.34% in Q4 2022 from the same period last year, while for Sep 2023 it was 11315518.9%, marking a year-over-year decrease of 113059968200.0%. This contributed to the annual value of 15931.33% for FY2022, which is 143166500.0% down from last year.
  • Immuneering's EBITDA Margin amounted to 2886419.34% in Q4 2022, which was down 28807077700.0% from 33364.36% recorded in Q3 2022.
  • Over the past 5 years, Immuneering's EBITDA Margin peaked at 644.49% during Q3 2020, and registered a low of 2886419.34% during Q4 2022.
  • For the 3-year period, Immuneering's EBITDA Margin averaged around 268262.7%, with its median value being 1771.06% (2021).
  • In the last 5 years, Immuneering's EBITDA Margin plummeted by -4601000bps in 2021 and then tumbled by 2000000000bps in 2022.
  • Quarter analysis of 3 years shows Immuneering's EBITDA Margin stood at 877.48% in 2020, then crashed by -551bps to 5711.57% in 2021, then plummeted by -50436bps to 2886419.34% in 2022.
  • Its EBITDA Margin was 2886419.34% in Q4 2022, compared to 33364.36% in Q3 2022 and 12223.67% in Q2 2022.